Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
2013
Aim: This study aimed to identify predictive/prognostic factors in castration-resistant prostate cancer patients treated with cabazitaxel. Patients & methods: Patients were enrolled from March 2011 to December 2011 in an international expanded access program. In January 2012, when cabazitaxel became commercially available, a prospective study was initiated at University Federico II of Naples and at Rionero in Vulture Hospital. Results: Forty-seven patients were enrolled in this study. Patients received a median of nine cycles of cabazitaxel. Median progression-free survival was 7.0 months (95% CI: 5.7–8.0). Seventeen patients were still alive at the time of the analysis, with a median overall survival of 14 months (95% CI: 11–16). At multivariate analysis, a higher Gleason score (≥8) appeared to be associated with prolonged progression-free survival (hazard ratio: 0.36; 95% CI: 0.18–0.72); however, the higher Gleason score showed no statistical impact on overall survival. Conclusion: We hypothesize that t...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
30
Citations
NaN
KQI